

Estimate change	↑
TP change	↑
Rating change	↔

Motilal Oswal values your support in the Asiamoney Brokers Poll 2021 for India Research, Sales, Corporate Access and Trading team. We [request your ballot](#).



Bloomberg	GRASIM IN
Equity Shares (m)	657
M.Cap.(INRb)/(USDb)	985.6 / 13.3
52-Week Range (INR)	1610 / 609
1, 6, 12 Rel. Per (%)	-10/13/92
12M Avg Val (INR M)	2363

#### Financial Snapshot (INR b)

Y/E MARCH	2021	2022E	2023E
Sales	123.9	187.3	211.4
EBITDA	15.6	33.4	34.8
Adj. PAT	8.9	24.6	24.7
EBITDA Margin (%)	12.6	17.9	16.5
S/A Adj. EPS (INR)	13.5	37.5	37.5
S/A EPS Gr. (%)	-29.4	176.5	0.1
Consol EPS (INR)	67.9	102.3	110.3
BV/Sh. (INR)	652.6	686.1	719.5
<b>Ratios</b>			
Net D:E	0.0	0.0	0.0
RoE (%)	2.1	5.5	5.2
RoCE (%)	2.7	7.0	6.6
<b>Valuations</b>			
P/E (x)	110.6	40.0	40.0
P/BV (x)	2.3	2.2	2.1
Div. Yield (%)	0.3	0.3	0.3
FCF Yield (%)	1.2	0.9	0.9

#### Shareholding pattern (%)

As On	Jun-21	Mar-21	Jun-20
Promoter	42.1	41.8	40.3
DII	16.0	16.8	21.4
FII	15.3	14.6	12.9
Others	26.6	26.7	25.5

FII Includes depository receipts

**CMP: INR1,498**
**TP: INR1,590 (+6%)**
**Neutral**

#### Higher VSF exports cushion weak domestic demand

##### Margin surprises positively

- GRASIM's 1QFY22 result surprised positively on EBITDA margin, which came in at 19.7% (est. 17.2%), driven by sustained cost reduction and better realization in the Chemicals business. EBITDA stood at INR7.4b v/s a loss of INR2.3b in 1QFY21.
- We raise our FY22E/FY23E standalone EBITDA by 18%/6% to factor in an improved demand outlook and better margin for both the VSF and Chemicals. The holding company discount of 46% is in line with its 10-year average of 48%. We maintain our **Neutral** rating.

#### Realization and margin in Chemicals drives 17% EBITDA beat

- Revenue/EBITDA/adjusted PAT (excluding the Fertilizer business in the base quarter) stood at INR37.6b/INR7.4b/INR4.5b as against INR13.4b/-INR2.3b/-INR2.5b in 1QFY21 and was 2%/17%/36% higher than our estimate. The beat was led by better than expected performance in the Chemicals business on the back of higher realization and margin.
- Revenue for the VSF segment improved 277% YoY to INR21b, led by higher volumes (+173% YoY). EBITDA stood at INR4.9b v/s a loss of INR1.1b in 1QFY21, with margin at 23.2% (est. 21%).
- In the VSF business, the management increased the share of exports to 31% in 1QFY22 v/s 11% in 4QFY21, which cushioned the impact of the slowdown in the domestic Textile sector.
- Revenue/EBITDA for the Chemicals business rose 105%/571% YoY (low base) to INR14.4b/INR2.8b, led by better realization (+19% YoY) and higher margin at 19.2% (+13.3pp YoY, est. 13%).

#### Highlights from the management commentary

- Domestic demand for Fiber is witnessing a gradual uptick, with the easing of restrictions across states.
- VSF expansion at Vilayat has progressed as per schedule, and the first line of 300TPD is expected to be commissioned in 2QFY22. Another line of 300TPD will be commissioned in 3QFY22.
- The management is focused on: 1) increasing the VAP mix to 40% by CY25 in both VSF and Chemicals, and 2) rationalizing cost of production across all businesses.
- Divestment of its Fertilizer business is expected to be completed in 2QFY22. The management has guided at an enterprise value of INR16b as against its earlier guidance of INR26.5b as it has received INR10b of government subsidies, which was due earlier.

### Valuation and view

- While the outlook for the Viscose business has improved further, we expect margin for the Chemicals segment to improve. However, it will remain weak due to significant capacity expansion over the next two years.
- Given GRASIM's conglomerate business structure, we value it on a SoTP basis at INR1,590. Our TP values: a) the standalone business (Viscose, Chemicals, etc.) at 6x FY23E EV/EBITDA, b) UTCEM at a 50% holding company discount to our TP, and c) other listed investments (ABCAP, IDEA, HNDL, and ABFRL) at a 50% holding company discount to its market price. We maintain our **Neutral** rating.

### Standalone quarterly performance

Y/E March (Standalone)	FY21								FY22				FY21	FY22E	(INR m) 1QE (%)			
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE										
									FY21	FY22E	Var.	1QE						
<b>Net Sales</b>	<b>13,357</b>	<b>29,598</b>	<b>36,966</b>	<b>43,943</b>	<b>37,627</b>	<b>47,950</b>	<b>49,203</b>	<b>52,519</b>	<b>123,864</b>	<b>187,299</b>	<b>36,941</b>	<b>2</b>						
YoY Change (%)	-73.3	-38.3	-17.8	1.9	181.7	62.0	33.1	19.5	-33.4	51.2	174.3							
<b>EBITDA</b>	<b>-2,257</b>	<b>3,346</b>	<b>6,445</b>	<b>8,109</b>	<b>7,402</b>	<b>9,170</b>	<b>8,519</b>	<b>8,346</b>	<b>15,643</b>	<b>33,437</b>	<b>6,338</b>	<b>17</b>						
Margin (%)	-16.9	11.3	17.4	18.5	19.7	19.1	17.3	15.9	12.6	17.9	17.2							
Depreciation	2,029	2,056	2,051	2,145	2,018	2,250	2,350	2,505	8,282	9,123	2,200							
Interest	658	649	516	536	581	600	570	664	2,360	2,415	500							
Other Income	992	2,816	638	692	649	7,901	850	805	5,137	10,205	900	-28						
<b>PBT before EO Items</b>	<b>-3,951</b>	<b>3,456</b>	<b>4,515</b>	<b>6,119</b>	<b>5,453</b>	<b>14,220</b>	<b>6,449</b>	<b>5,982</b>	<b>10,139</b>	<b>32,104</b>	<b>4,538</b>	<b>20</b>						
Extraordinary Inc./(Exp.)	-577	0	0	-233	0	0	0	0	-810	0	0							
<b>PBT after EO Items</b>	<b>-4,529</b>	<b>3,456</b>	<b>4,515</b>	<b>5,886</b>	<b>5,453</b>	<b>14,220</b>	<b>6,449</b>	<b>5,982</b>	<b>9,329</b>	<b>32,104</b>	<b>4,538</b>	<b>20</b>						
Tax	-1,414	175	1,208	1,256	993	2,844	1,806	1,813	1,224	7,456	1,271							
Rate (%)	31.2	5.1	26.7	21.3	18.2	20.0	28.0	30.3	13.1	23.2	28.0							
<b>Reported PAT</b>	<b>-3,115</b>	<b>3,281</b>	<b>3,308</b>	<b>4,630</b>	<b>4,459</b>	<b>11,376</b>	<b>4,643</b>	<b>4,169</b>	<b>8,105</b>	<b>24,648</b>	<b>3,268</b>	<b>36</b>						
<b>Adj. PAT</b>	<b>-2,538</b>	<b>3,281</b>	<b>3,308</b>	<b>4,863</b>	<b>4,459</b>	<b>11,376</b>	<b>4,643</b>	<b>4,169</b>	<b>8,914</b>	<b>24,648</b>	<b>3,268</b>	<b>36</b>						
Margin (%)	-19.0	11.1	8.9	11.1	11.9	23.7	9.4	7.9	7.2	13.2	8.8							
YoY Change (%)	-157.7	-37.7	75.3	350.8	-275.7	246.7	40.4	-14.3	-29.4	176.5	-223.7							

E: MOFSL estimates; FY20 earnings include the Fertilizer business and hence are not comparable



### Highlights from the management commentary

#### Viscose business

- The share of value-added products in the overall sales mix improved to 26% in 1QFY22 v/s 22% in FY21.
- It brought forward the Harihar plant maintenance shutdown to May'21 (earlier scheduled for Sep'21).
- Domestic demand for Fiber is witnessing a gradual uptick, with the easing of restrictions across states.
- In China, VSF prices have stabilized at RMB13,000 after moderating to RMB12,871 in Jun'21 from RMB15,805 in Mar'21. Inventory at the plants has risen to 24 days in Jun'21 from 13 days in Mar'21, which led to a readjustment of production levels by Chinese VSF players.
- Deceleration in restocking during 4QFY21 and seasonal factors led to a lower VSF demand in China, resulting in a moderation in prices in 1QFY22.
- Revenue/EBITDA for VFY stood at INR3.4b/INR0.4b.

#### Chemicals business

- In India, the Chemicals business was impacted due to the second COVID wave as demand for Chlorine value added products from MSMEs remained subdued in 1QFY22. Weak demand from Textiles and Organic Chemicals and excess supply capped the rise in domestic Caustic Soda prices.

- In 1QFY22, international Caustic Soda prices remained strong, driven by supply outages due to supply constraints/maintenance activities and modest improvement in demand.
- Caustic Soda capacity utilization stood at 85% in 1QFY22, while Chlorine consumption in VAPs stood at 28%.
- The Advanced Materials (Epoxy) business has delivered a robust performance, led by strong realization and robust demand in the Wind and Auto segments.

#### **Capex**

- VSF expansion at Vilayat has progressed as per schedule, and the first line of 300TPD is expected to be commissioned in 2QFY22. Another line of 300TPD will be commissioned in 3QFY22.
- In the Chlor-Alkali business, the Rehla plant/CMS plant/BB Puram (Phase I)/Vilayat (Phase I) is expected to be commissioned in 2Q/2Q/2H/2HFY22 and will have a capacity of 91kt/54.8kt/73kt/73kt. Vilayat (Phase II)/BB Puram (Phase II) is expected to be commissioned in FY23, and will have a capacity of 73kt/73kt.
- Epoxy expansion of 125kt is expected to be commissioned in FY24.
- The management has guided at a capex of INR25b in FY22 (excluding the Paints and Fertilizer business).

#### **Debt**

- Standalone gross debt stood at INR48.6b and net debt stood at INR18.2b v/s INR9.1b in Mar'21.
- Consolidated gross debt stood at INR254.3b and net debt stood at INR89.8b v/s INR86.3b in Mar'21.

#### **Other highlights**

- The management is focused on: 1) increasing the VAP mix to 40% by CY25 in both VSF and Chemicals, and 2) rationalizing cost of production across all businesses.
- Divestment of its Fertilizer business is expected to be completed in 2QFY22. The management has guided at an enterprise value of INR16b as against its earlier guidance of INR26.5b as it has received INR10b of government subsidies, which was due earlier.
- The Paint business is progressing as planned. Land acquisition for setting up plants in different states is in process and so are its project engineering plans.
- Freight has emerged as a major challenge across the globe, while raw material prices have gone up across businesses.
- The management expects businesses to resume their growth trajectory on the assumption of a lower impact from the third COVID wave.

## Key exhibits

### Exhibit 1: SoTP valuation

	INR b	(INR/share)
UltraTech Cement at the target price	1,449	2,204
Aditya Birla Capital at CMP	148	225
Vodafone Idea at CMP	22	33
Hindalco at CMP	41	62
Aditya Birla Fashion and Retail at CMP	18	28
<b>Total value of listed investments</b>	<b>1,677</b>	<b>2,551</b>
Conglomerate discount at 50%	839	1,275
Net value of listed investments post discount	839	1,275
Parent business at 6x FY23E EV/EBITDA	207	315
<b>Total equity value</b>	<b>1,046</b>	<b>1,590</b>
<b>SoTP-based target price</b>		<b>1,590</b>

Source: MOFSL, Company

### Exhibit 2: VSF's business performance

Particulars (Rs. Cr.)	Capex spent Q1 FY22	Balance Budget	1QFY22	1QFY21	YoY (%)	4QFY21	QoQ (%)
Viscose Staple Fibre (from 578 KTPA to 810 KTPA)							
Capacity Expansion	189	757					
Normal Modernisation and Maintenance Capex	50	344					
<b>Chemical (from 1,147 KTPA to 1,530 KTPA)</b>							
Capacity Expansion, Normal Modernisation and Maintenance	109	591					
<b>Capex related to other businesses</b>							
VFY, Epoxy, Textiles and Insulator	28	432					
<b>Total</b>	<b>376</b>	<b>2,124</b>					

Source: MOFSL, Company

### Exhibit 3: Performance of the Chemicals business

	1QFY22	1QFY21	YoY (%)	4QFY21	QoQ (%)
Production (tonne)	242,000	139,000	74.1	265,000	-8.7
Sales volume (tonne)	238,000	138,000	72.5	267,000	-10.9
Net Turnover (INR m)	14,360	7,020	104.6	14,720	-2.4
PBIT margin (%)	19.2	5.8	13.3	12.6	6.6
EBITDA (INR m)	2,750	410	570.7	1,850	48.6

Source: MOFSL, Company

## Valuation and view

### Strong outlook for VSF, the same for Chemicals improves

While the outlook for the Viscose business has improved further, we expect margin for the Chemicals segment to improve on account of cost reduction and a better demand outlook. We expect VSF margin to recover to INR32/kg in FY22E, aided by: 1) strong demand for VSF, and 2) supportive regional dynamics as VSF inventory at plants in China has declined significantly (22 days at present from 45 days in Apr'20).


The margin for Chemicals, while recovering from the COVID-19 lows, is expected to improve on a better demand outlook. However, it will remain weak in the medium term, given the significant capacity addition over the next two years.

**Exhibit 4: Margin trend in VSF and Chemicals**

EBITDA/kg	FY11	FY12	FY13	FY14	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
VSF	44.1	34.3	25.1	17.1	9.3	17.6	26.7	29.2	29.9	18.1	23.1	32.0	28.0
Chemicals	6.8	7.5	11.9	9.2	16.0	8.9	10.9	15.1	18.2	10.2	6.6	10.5	10.0

Source: MOFSL, Company

Given GRASIM's conglomerate business structure, we value it on a SoTP basis. Our TP values: a) the standalone business (Viscose, Chemicals, etc.) at 6x FY23E EV/EBITDA, b) UTCEM at a 50% holding company discount to our TP, and c) other listed investments (ABCAP, IDEA, HNDL, and ABFRL) at a 50% holding company discount to its market price. We thus arrive at a fair value of INR1,590 per share. We maintain our **Neutral** rating.

**Exhibit 5: Holding company discount at 46% below its long-term average of 48%**

Source: MOFSL, Company

## Financials and valuations

Standalone Income Statement								(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
<b>Net Sales</b>	<b>89,692</b>	<b>1,03,457</b>	<b>1,57,858</b>	<b>2,05,504</b>	<b>1,86,094</b>	<b>123,864</b>	<b>187,299</b>	<b>211,440</b>
Change (%)	41.4	15.3	52.6	30.2	-9.4	-33.4	51.2	12.9
Total Expenditure	74,766	81,909	1,27,083	1,64,793	1,62,989	108,220	153,862	176,619
<b>EBITDA</b>	<b>14,927</b>	<b>21,548</b>	<b>30,775</b>	<b>40,712</b>	<b>23,105</b>	<b>15,643</b>	<b>33,437</b>	<b>34,820</b>
Change (%)	121.3	44.4	42.8	32.3	-43.2	-32.3	113.7	4.1
Margin (%)	16.6	20.8	19.5	19.8	12.4	12.6	17.9	16.5
Depreciation	4,449	4,461	6,277	7,604	8,468	8,282	9,123	12,118
<b>EBIT</b>	<b>10,478</b>	<b>17,086</b>	<b>24,499</b>	<b>33,108</b>	<b>14,638</b>	<b>7,362</b>	<b>24,314</b>	<b>22,702</b>
Int. and Finance Charges	1,474	576	1,281	1,991	3,039	2,360	2,415	3,264
Other Income - Rec.	3,585	4,739	4,614	5,680	5,255	5,137	10,205	11,943
<b>PBT and EO Items</b>	<b>12,588</b>	<b>21,249</b>	<b>27,831</b>	<b>36,797</b>	<b>16,854</b>	<b>10,139</b>	<b>32,104</b>	<b>31,380</b>
Change (%)	77.0	68.8	31.0	32.2	-54.2	-39.8	216.6	-2.3
Extra-ordinary Income	-292	0	-2,726	-23,680	-2,941	-810	0	1
<b>PBT but after EO Items</b>	<b>12,297</b>	<b>21,249</b>	<b>25,105</b>	<b>13,117</b>	<b>13,913</b>	<b>9,329</b>	<b>32,104</b>	<b>31,381</b>
Tax	2,590	5,649	7,446	7,964	1,214	1,224	7,456	6,718
Tax Rate (%)	21.1	26.6	29.7	60.7	8.7	13.1	23.2	21.4
<b>Reported PAT</b>	<b>9,706</b>	<b>15,600</b>	<b>17,659</b>	<b>5,153</b>	<b>12,700</b>	<b>8,105</b>	<b>24,648</b>	<b>24,663</b>
<b>PAT Adj. for EO items</b>	<b>9,998</b>	<b>15,600</b>	<b>20,385</b>	<b>28,833</b>	<b>12,625</b>	<b>8,914</b>	<b>24,648</b>	<b>24,662</b>
Change (%)	79.8	56.0	30.7	41.4	-56.2	-29.4	176.5	0.1
Margin (%)	11.1	15.1	12.9	14.0	6.8	7.2	13.2	11.7

Standalone Balance Sheet								(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
Equity Share Capital	934	934	1,315	1,315	1,316	1,316	1,316	1,316
Reserves	1,37,785	1,61,376	4,46,584	4,18,277	3,75,425	428,162	450,178	472,209
Revaluation Reserves	0	0	0	0	0	0	0	0
<b>Net Worth</b>	<b>1,38,718</b>	<b>1,62,310</b>	<b>4,47,898</b>	<b>4,19,592</b>	<b>3,76,740</b>	<b>429,479</b>	<b>451,494</b>	<b>473,525</b>
Loans	16,152	7,015	25,825	33,108	50,681	41,634	41,634	51,634
Deferred liabilities	4,941	6,630	18,350	18,789	14,025	17,339	17,339	17,339
<b>Capital Employed</b>	<b>1,59,811</b>	<b>1,75,954</b>	<b>4,92,073</b>	<b>4,71,488</b>	<b>4,41,447</b>	<b>488,452</b>	<b>510,468</b>	<b>542,498</b>
Gross Block	77,947	81,549	1,27,316	1,38,501	1,54,142	158,742	188,940	228,940
Less: Accum. Deprn.	8,316	12,681	19,125	26,166	33,310	39,302	48,425	60,544
<b>Net Fixed Assets</b>	<b>69,631</b>	<b>68,868</b>	<b>1,08,191</b>	<b>1,12,335</b>	<b>1,20,832</b>	<b>119,439</b>	<b>140,514</b>	<b>168,396</b>
Capital WIP	3,177	3,755	7,451	15,672	27,919	40,334	30,334	20,334
Non-Current Investments/Strategic	58,869	74,241	3,35,867	2,81,616	2,56,621	305,230	305,230	305,230
Current - Financial	12,127	15,723	19,599	29,660	20,141	31,167	31,167	31,167
<b>Curr. Assets</b>	<b>34,161</b>	<b>35,924</b>	<b>66,067</b>	<b>78,850</b>	<b>69,433</b>	<b>47,411</b>	<b>65,005</b>	<b>84,141</b>
Inventory	16,054	17,327	25,917	29,317	26,262	21,790	30,467	34,436
Account Receivables	9,924	11,896	26,093	34,841	29,053	13,120	17,773	20,087
Cash and Bank Balance	350	527	419	425	789	1,327	5,592	18,445
Others	7,833	6,174	13,639	14,268	13,328	11,174	11,174	11,174
<b>Curr. Liability and Prov.</b>	<b>18,152</b>	<b>22,557</b>	<b>45,103</b>	<b>46,643</b>	<b>53,499</b>	<b>55,129</b>	<b>61,783</b>	<b>66,771</b>
Account Payables	5,932	11,259	22,534	23,738	26,648	27,069	33,723	38,711
Provisions	1,702	1,626	5,087	4,614	5,514	3,249	3,249	3,249
Other Liabilities	10,518	9,672	17,481	18,291	21,337	24,811	24,811	24,811
<b>Net Current Assets</b>	<b>16,008</b>	<b>13,367</b>	<b>20,965</b>	<b>32,206</b>	<b>15,934</b>	<b>-7,719</b>	<b>3,222</b>	<b>17,370</b>
<b>Appl. of Funds</b>	<b>1,59,811</b>	<b>1,75,955</b>	<b>4,92,073</b>	<b>4,71,489</b>	<b>4,41,447</b>	<b>488,452</b>	<b>510,468</b>	<b>542,498</b>

E: MOFSL estimates

## Financials and valuations

Standalone Ratios								(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
<b>Share price</b>								
EPS	107.1	167.1	31.0	43.8	19.2	13.5	37.5	37.5
Cash EPS	31.0	43.0	40.6	55.4	32.1	26.1	51.3	55.9
BV/Share	297.2	347.7	681.4	638.1	572.7	652.6	686.1	719.5
DPS	3.6	5.5	6.2	7.0	4.0	4.0	4.0	4.0
<b>Valuation</b>								
P/E						110.6	40.0	40.0
PEG (x)						-3.8	0.2	706.1
Cash P/E						57.3	29.2	26.8
P/BV						2.3	2.2	2.1
EV/Sales						0.1	0.0	0.0
EV/EBITDA						63.6	29.6	28.4
Dividend Yield (%)						0.3	0.3	0.3
<b>Return Ratios (%)</b>								
RoE	7.2	9.6	4.6	6.9	3.4	2.1	5.5	5.2
RoCE	9.1	12.9	6.1	8.6	4.7	2.7	7.0	6.6
RoIC	6.0	7.8	5.4	2.8	3.0	1.4	3.9	3.6
<b>Working Capital Ratios</b>								
Debtor (Days)	40	42	60	62	57	39	35	35
Asset Turnover (x)	0.6	0.6	0.3	0.4	0.4	0.3	0.4	0.4
<b>Leverage Ratio</b>								
Debt/Equity	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1

Standalone Cash Flow Statement								(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
<b>OP/(Loss) before Tax</b>								
OP/(Loss) before Tax	12,297	21,249	25,131	13,117	13,913	10,139	32,104	31,381
Depreciation	4,449	4,461	6,277	7,604	8,468	8,282	9,123	12,118
Interest and Finance Charges	930	-591	701	941	2,604	1,867	2,415	3,264
Direct Taxes Paid	-3,212	-2,210	-5,233	-5,123	-2,154	-1,786	-7,456	-6,718
(Inc.)/Dec. in WC	571	2,802	-2,796	-10,752	12,855	9,350	-6,675	-1,295
<b>CF from Operations</b>	<b>15,034</b>	<b>25,712</b>	<b>24,080</b>	<b>5,788</b>	<b>35,686</b>	<b>27,852</b>	<b>29,510</b>	<b>38,751</b>
Others	-1,628	-3,118	-551	19,767	-501	-3,878	0	0
<b>CF from Operations incl. EO</b>	<b>13,407</b>	<b>22,593</b>	<b>23,529</b>	<b>25,555</b>	<b>35,185</b>	<b>23,974</b>	<b>29,510</b>	<b>38,751</b>
(Inc.)/Dec. in FA	-6,405	-4,217	-10,521	-20,384	-27,032	-11,830	-20,198	-30,000
<b>Free Cash Flow</b>	<b>7,002</b>	<b>18,376</b>	<b>13,007</b>	<b>5,171</b>	<b>8,153</b>	<b>12,144</b>	<b>9,312</b>	<b>8,751</b>
(Pur.)/Sale of Investments	-3,221	-7,674	-1,850	-1,488	18,104	-8,976	0	0
Others	2,667	3,512	-6,754	-687	-36,033	12,490	0	0
<b>CF from Investments</b>	<b>-6,958</b>	<b>-8,378</b>	<b>-19,125</b>	<b>-22,559</b>	<b>-44,961</b>	<b>-8,316</b>	<b>-20,198</b>	<b>-30,000</b>
Issue of Shares	53	26	23	86	90	126	0	0
Inc./(Dec.) in Debt	-3,275	-11,322	942	3,504	17,475	-9,170	0	10,000
Interest Paid	-1,577	-597	-1,417	-2,050	-2,103	-3,241	-2,415	-3,264
Dividend Paid	-1,774	-2,037	-3,660	-4,050	-4,598	-2,622	-2,633	-2,634
Others	-58	-108	-399	-481	-725	-213	0	0
<b>CF from Fin. Activity</b>	<b>-6,631</b>	<b>-14,038</b>	<b>-4,512</b>	<b>-2,990</b>	<b>10,140</b>	<b>-15,120</b>	<b>-5,047</b>	<b>4,102</b>
<b>Inc./Dec. in Cash</b>	<b>-182</b>	<b>177</b>	<b>-109</b>	<b>7</b>	<b>364</b>	<b>537</b>	<b>4,265</b>	<b>12,853</b>
Opening Balance	532	350	527	418	425	789	1,327	5,592
<b>Closing Balance</b>	<b>350</b>	<b>527</b>	<b>418</b>	<b>425</b>	<b>789</b>	<b>1,327</b>	<b>5,592</b>	<b>18,445</b>

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/ListOf%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL , including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months

- other potential conflict of interests with respect to any recommendation and other related information and opinions., however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Patel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website [www.motilaloswal.com](http://www.motilaloswal.com); CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai-400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)\*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579; PMS: INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP00000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.: 022-71881085.

\* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.